Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: A theoretic model

Journal of Nuclear Medicine

Volumn 47, Issue 4, 2006, Pages 660-667

  Madsen, Mark T ^a   Bushnell, David L ^a   Juweid, Malik E ^a   Menda, Yusuf ^a   O'Dorisio, M Sue ^a   O'Dorisio, Thomas ^a   Besse, Ian M ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

131I MIBG; 90Y DOTATOC; Combined agent therapy; Neuroendocrine cancer; Radionuclide therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANINE1 TYROSINE3 OCTREOTIDE Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (3 IODOBENZYL)GUANIDINE; (DOTA(0) PHE(1) TYR(3))OCTREOTIDE; (DOTA(0)-PHE(1)-TYR(3))OCTREOTIDE; DRUG DERIVATIVE; OCTREOTIDE; RADIOACTIVE IODINE; YTTRIUM;

ARTICLE; DOSE CALCULATION; DOSIMETRY; DRUG POTENTIATION; MATHEMATICAL COMPUTING; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; THEORETICAL MODEL; BIOLOGICAL MODEL; DRUG COMBINATION; HUMAN; RADIATION DOSE;

3-IODOBENZYLGUANIDINE; DRUG THERAPY, COMBINATION; HUMANS; IODINE RADIOISOTOPES; MODELS, BIOLOGICAL; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIATION DOSAGE; RADIOPHARMACEUTICALS; YTTRIUM RADIOISOTOPES;

EID: 33745114778     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Schramm A, Schulte JH, Klein-Hitpass L, et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene. 2005;24:7902-7912.
2. Jensen R, Doherty G. Carcinoid tumors and carcinoid syndrome. In: Devita VT, ed. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001.
3. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417-418.
4. 131I-MIBG. Pediatr Blood Cancer. 2005;44:232-239.
5. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Cancer. 2004;101:1987-1993.
6. 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med. 2003;44:1556-1560.
7. 111In- DTPA-octreotide. Eur J Nucl Med. 2001;28:1743-1750.
8. Stabin M, Stubbs J, Toohey R. Radiation Dose Estimates for Radiopharmaceuticals. Oak Ridge, TN: Oak Ridge Institute for Science and Education; 1996.
9. Lashford LS, Lewis IJ, Fielding SL, et al. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol. 1992;10:1889-1896.
10. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. Eur J Nucl Med. 2001;28:1447-1449.
11. 131I-MIBG. J Nucl Med. 2001;42:1713-1721.
12. 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46:92S-98S.
13. 111In- pentetreotide in carcinoid tumours. Eur J Cancer. 1996;32A:1924-1932.
14. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895-902.
15. Quigley A, Buscombe J, Gopinath G, Caplin M, Hilson A. In-vivo characteristics of the functional aspects of carcinoid tumors by imaging somatostatin receptors and amine uptake [abstract]. J Nucl Med. 2003;44(suppl):74P.
16. Nocaudie-Calzada M, Huglo D, Carnaille B, Proye C, Marchandise X. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours. Eur J Nucl Med. 1996;23:1448-1454.